283
Participants
Start Date
June 15, 2023
Primary Completion Date
May 15, 2025
Study Completion Date
July 5, 2025
CYP2C19 Genotype-Guided Clopidogrel Treatment
Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel
An antiplatelet drug alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor, or prasugrel).
The Conventional Clopidogrel Treatment
Clopidogrel as a component of preventive antiplatelet treatment such as double antiplatelet treatment (DAPT), or clopidogrel combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel).
1st University Clinic of the Tbilisi State Medical University, Tbilisi
Cardio Expert Ltd., Clinic Cardio, Tbilisi
T. Oragvelidze Cardiology Center, Tbilisi
Tbilisi Institute of Medicine, Tbilisi
Tbilisi State Medical University
OTHER
Vistamedi Ltd.
INDUSTRY